Scailyte hits twin peaks: Extends Series A funding to USD 8 Million and transfers endometriosis diagnostic assets to Hera Biotech
08.01.2024
The strategic agreement and the recent funding focus on enhancing tissue-based diagnostic programs for endometriosis, promising a substantial leap forward in precision and effectiveness. While Scailyte continues to develop its platform technologies with remaining assets, the acquisition positions Hera Biotech in the first line for innovative solutions for diagnosing this complex and often challenging medical condition.
 Scailyte's team
|
 |
Last week, Scailyte, a Swiss innovator in single-cell and AI-guided biomarker discovery, agreed with US-based Hera Biotech, marking a crucial moment as Hera acquires Scailyte's endometriosis diagnostic testing assets and associated intellectual property.
Scailyte, rooted in Basel and stemming from ETH Zurich, boasts an AI platform presenting complex disease patterns from single-cell data, resolving hidden "single-cell" secrets, and enabling the identification of clinically relevant biomarker signatures. Following a recent extension of its Series A funding, raising a total of USD 8 million, Scailyte has sealed this transformative deal, the financial details of which remain undisclosed. These extra funds will be crucial in boosting Scailyte's influence in immuno-oncology, broadening its business collaborations and expanding market presence.
The intellectual property acquisition consolidates the only two tissue-based diagnostic programs for endometriosis, affirming a significant step in advancing diagnostic capabilities. Collaborative research by both companies and their academic partners has unveiled substantial transcriptomic changes in endometrium samples from endometriosis patients compared to controls.
Leveraging Scailyte's deep sequencing discovery platform, researchers analyzed over 6 billion transcriptomic data points from 169 patients. The outcome? Complementary biomarkers and assays, promising accurate and noninvasive endometriosis diagnosis.
Hera Biotech, founded to address unmet needs in women's health, especially reproductive medicine, aims to commercialize a non-surgical method for the definitive early diagnosis and staging of endometriosis. The company plans to launch its first diagnostic product, employing the Scailyte platform, in the US fertility market by late 2024.
Scailyte was ranked among the TOP 100 Swiss Startup from 2019 to 2021, participated in Venture Leaders Life Sciences in 2019, and won the first stage of Venture Kick in 2017.
"Venture Leaders Life Sciences brings together a group of 10 promising Swiss medtech/biotech startups, which offers valuable exchange between peers, as well as makes it attractive for investors to meet with the group and open doors for the startups. You can think of the program as a premium Swiss chocolate box: there is something sweet for everyone in it," commented Peter Nestorov, CEO and Co-founder of Scailyte.
Scailyte's team
Scailyte, rooted in Basel and stemming from ETH Zurich, boasts an AI platform presenting complex disease patterns from single-cell data, resolving hidden "single-cell" secrets, and enabling the identification of clinically relevant biomarker signatures. Following a recent extension of its Series A funding, raising a total of USD 8 million, Scailyte has sealed this transformative deal, the financial details of which remain undisclosed. These extra funds will be crucial in boosting Scailyte's influence in immuno-oncology, broadening its business collaborations and expanding market presence.
The intellectual property acquisition consolidates the only two tissue-based diagnostic programs for endometriosis, affirming a significant step in advancing diagnostic capabilities. Collaborative research by both companies and their academic partners has unveiled substantial transcriptomic changes in endometrium samples from endometriosis patients compared to controls.
Leveraging Scailyte's deep sequencing discovery platform, researchers analyzed over 6 billion transcriptomic data points from 169 patients. The outcome? Complementary biomarkers and assays, promising accurate and noninvasive endometriosis diagnosis.
Hera Biotech, founded to address unmet needs in women's health, especially reproductive medicine, aims to commercialize a non-surgical method for the definitive early diagnosis and staging of endometriosis. The company plans to launch its first diagnostic product, employing the Scailyte platform, in the US fertility market by late 2024.
Scailyte was ranked among the TOP 100 Swiss Startup from 2019 to 2021, participated in Venture Leaders Life Sciences in 2019, and won the first stage of Venture Kick in 2017.
"Venture Leaders Life Sciences brings together a group of 10 promising Swiss medtech/biotech startups, which offers valuable exchange between peers, as well as makes it attractive for investors to meet with the group and open doors for the startups. You can think of the program as a premium Swiss chocolate box: there is something sweet for everyone in it," commented Peter Nestorov, CEO and Co-founder of Scailyte.
Scailyte's team